Preventing breast cancer resistance to CDK4/6 inhibitors using genomic findings
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. ...
Mar 8, 2026
0
1









